Cited by 522Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and ApplicationsCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Open access

Nishino, Mizuki, Giobbie-Hurder, Anita, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H., Hodi, F. Stephen·2013·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-13-0895PMC PMC3740724

Open this paper in CoChat — free account

Abstract

PURPOSE: Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in patients with advanced melanoma treated with ipilimumab. EXPERIMENTAL DESIGN: Fifty-seven patients with advanced melanoma treated with ipilimumab in a phase II, expanded access trial were studied. Bidimensional tumor measurement records prospectively conducted during the trial were reviewed to generate a second set of measurements using unidimensional, longest diameter measurements. The percent changes of measurements at follow-up, best overall response, and time-to-progression (TTP) were compared between bidimensional and unidimensional irRC. Interobserver variability for bidimensional and unidimensional measurements was assessed in 25 randomly selected patients. RESULTS: The percent changes at follow-up scans were highly concordant between the 2 criteria (Spearman r: 0.953-0.965, first to fourth follow-up). The best immune-related response was highly concordant between the 2 criteria (κw = 0.881). TTP was similar between the bidimensional and unidimensional assessments (progression-free at 6 months: 70% vs. 81%, respectively). The unidimensional measurements were more reproducible than bidimensional measurements, with the 95% limits of agreement of (-16.1%, 5.8%) versus (-31.3%, 19.7%), respectively. CONCLUSION: irRC using the unidimensional measurements provided highly concordant response assessment compared with the bidimensional irRC, with less measurement variability. The use of unidimensional irRC is proposed to assess response to immunotherapy in solid tumors, given its simplicity, higher reproducibility, and high concordance with the bidimensional irRC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-0895

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
A concordance correlation coefficient to evaluate reproducibility.
Lin, L. I.-K. (1989) · Biometrics · doi:10.2307/2532051 · Cited by 8,785
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195

Show all 21 references

Sorted by citations

Items 201–300 of 520

Adverse effects and radiological manifestations of new immunotherapy agents
Tang, Y. Z., Szabados, B. E., Leung, C., & Sahdev, A. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180164 · Cited by 22
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
Sachpekidis, C., Kopp‐Schneider, A., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00832-4 · Cited by 23
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Zhang, P., Shi, S., Xu, J., Chen, Z., Song, L., Zhang, X., Cheng, Y., Zhang, Y., Ye, F., Li, Z., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113539 · Cited by 21
Evolving Treatment of Advanced Urothelial Cancer
Sridhar, S. S. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022137 · Cited by 21
Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
Qin, B., Jiao, X., & Zang, Y. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.05.005 · Cited by 21
Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learning
Huang, W., Wang, X., Zhong, R., Li, Z., Zhou, K., Lyu, Q., Han, J., Chen, T., Islam, M. T., Yuan, Q., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217930 · Cited by 20
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
Moreno, V., Roda, D., Pikiel, J., Trigo, J. M., Bosch‐Barrera, J., Drew, Y., Kristeleit, R. S., Hiret, S., Bajor, D. L., Cruz, P., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.05.013 · Cited by 20
Imaging endpoints for clinical trial use: a RECIST perspective
Litière, S., & Bogaerts, J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005092 · Cited by 18
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
Zambrana, F. R., Carril-Ajuria, L., de Liaño, A. G., Chanzá, N. M., Kopp, R. M., Castellano, D., & de Velasco, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102239 · Cited by 20
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment
Russo, G. M., Russo, A., Urraro, F., Cioce, F., Gallo, L., Belfiore, M., Sangiovanni, A., Napolitano, S., Troiani, T., Verolino, P., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13040793 · Cited by 12
Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive
Lei, X., Wang, Y., Shan, F., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., Ji, J., & Li, Z. (2023) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000944 · Cited by 19
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Disis, M. L., Adams, S. F., Bajpai, J., Butler, M. O., Curiel, T. J., Dodt, S. A., Doherty, L., Emens, L. A., Friedman, C. F., Gatti-Mays, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006624 · Cited by 24
Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
Hansen, E., Wang, X., Case, A. A., Puzanov, I. J., & Smith, T. (2018) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2018.05.015 · Cited by 19
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
Tsimberidou, A. M., Levit, L. A., Schilsky, R. L., Averbuch, S. D., Chen, D. S., Kirkwood, J. M., McShane, L. M., Sharon, E., Mileham, K. F., & Postow, M. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0426-7 · Cited by 19
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 20
Dynamic Contrast-Enhanced Computed Tomography–Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma
Mains, J. R., Donskov, F. N., Pedersen, E. M., Madsen, H. H. T., & Rasmussen, F. (2016) · Investigative Radiology · doi:10.1097/rli.0000000000000315 · Cited by 19
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
Wei, H., Jiang, H., & Song, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2464 · Cited by 18
Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
Zhao, Z., Bian, J., Zhang, J., Zhang, T., & Lu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843707 · Cited by 18
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics
Menis, J., Litière, S., Tryfonidis, K., & Golfinopoulos, V. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.19 · Cited by 20
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
Wang, Z., Wu, H., Xie, L., Lin, W., Liang, F., Li, J., Yang, Z., & Xu, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002114 · Cited by 17
RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do
Henze, J., Maintz, D. C., & ten Persigehl, T. (2016) · Current Radiology Reports · doi:10.1007/s40134-016-0178-4 · Cited by 18
Promising immunotherapy: Highlighting cytokine‐induced killer cells
Shirjang, S., Alizadeh, N., Mansoori, B., Mahmoodpoor, A., Kafil, H. S., Hojjat‐Farsangi, M., & Yousefi, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28250 · Cited by 18
Real-World Pseudoprogression: an Uncommon Phenomenon
Reckamp, K. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.011 · Cited by 17
USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation
Shao, N., Xi, L., Lv, Y., Idris, M., Zhang, L., Cao, Y., Xiang, J., Xu, X., Ong, B. X., Zhang, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56564-9 · Cited by 20
Nivolumab for advanced squamous cell lung cancer: what are the next steps?
de Mello, R. A., Pousa, I. D., & Pereira, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70074-4 · Cited by 17
Tailoring immunotherapy with liquid biopsy
Tie, J. (2020) · Nature Cancer · doi:10.1038/s43018-020-00113-4 · Cited by 17
Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy
Ippolito, D., Maino, C., Ragusi, M., Porta, M., Gandola, D. G., Franzesi, C. T., Giandola, T. P., & Sironi, S. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i5.323 · Cited by 17
Technical Feasibility and Safety of Image-Guided Biphasic Monopolar Pulsed Electric Field Ablation of Metastatic and Primary Malignancies
Kim, D., Suh, R. D., Chiang, J., Abtin, F. G., Genshaft, S. J., Hao, F., Lu, D., & Raman, S. S. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.08.003 · Cited by 17
Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma
Weiß, J., Notohamiprodjo, M., Bedke, J., Nikolaou, K., & Kaufmann, S. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000463 · Cited by 17
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
Michalarea, V., Fontana, E., Garces, A. I., Williams, A., Smyth, E. C., Picchia, S., Rao, S., Chau, I., Cunningham, D., & Bali, M. A. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.01.008 · Cited by 17
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
McLean, L. S., Cavanagh, K., Hicks, R., Callahan, J., Xie, J., Cardin, A., Lim, A., & Rischin, D. (2021) · Cancer Imaging · doi:10.1186/s40644-021-00426-2 · Cited by 17
Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises
Michaelidou, K., Agelaki, S., & Mavridis, K. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1724785 · Cited by 17
Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy
Guldbrandsen, K. F., Hendel, H. W., Langer, S. W., & Fischer, B. M. (2017) · Diagnostics · doi:10.3390/diagnostics7020023 · Cited by 16
Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
Gentzler, R. D., Riley, D., & Martin, L. W. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00969-w · Cited by 16
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
Mushti, S. L., Mulkey, F. A., Tang, S. W., Singh, H., Lemery, S. J., Goldberg, K. B., Sridhara, R., Keegan, P., Kluetz, P. G., Pazdur, R., et al. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00974-z · Cited by 16
Challenges of evaluating immunotherapy efficacy in solid tumors
Bai, R., Li, W., Du, N., & Cui, J. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.06.02 · Cited by 16
The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma
Hutson, T. E., Thoreson, G. R., Figlin, R. A., & Rini, B. I. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158892 · Cited by 15
Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug
Perlstein, D., Shlagman, O., Kogan, Y., Halevi-Tobias, K., Yakobson, A., Lazarev, I., & Agur, Z. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226869 · Cited by 17
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
Zheng, B., Shin, J. H., Li, H., Chen, Y., Guo, Y., & Wang, M. (2020) · Korean Journal of Radiology · doi:10.3348/kjr.2020.0404 · Cited by 15
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16
Atypical Patterns of Response and Progression in the Era of Immunotherapy Combinations
Ferrara, R., & Matos, I. G. (2020) · Future Oncology · doi:10.2217/fon-2020-0186 · Cited by 14
Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma
Yang, S. M., Kim, J.-E., Lee, J.-Y., Lee, J., & Lee, J. M. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0029 · Cited by 14
A Review of T-Cell Related Therapy for Osteosarcoma
Yoshida, K., Okamoto, M., Aoki, K., Takahashi, J., & Saito, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144877 · Cited by 14
Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy
Oriuchi, N., Sugawara, S., & Shiga, T. (2020) · Biomedicines · doi:10.3390/biomedicines8090371 · Cited by 15
Predictive value of 3′-deoxy-3′-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer
Sato, M., Umeda, Y., Tsujikawa, T., Mori, T., Morikawa, M., Anzai, M., Waseda, Y., Kadowaki, M., Kiyono, Y., Okazawa, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003079 · Cited by 13
Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects
Chowdhury, S., Bappy, M. H., Clocchiatti‐Tuozzo, S., Cheeti, S., Chowdhury, S., & Patel, V. R. (2021) · Cureus · doi:10.7759/cureus.20604 · Cited by 14
Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer
Doumas, S., Foukas, P. G., Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104477 · Cited by 14
Pseudoprogression and Measurement Variability
Nishino, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6759 · Cited by 14
Cancer Care Treatment Outcome Ontology: A Novel Computable Ontology for Profiling Treatment Outcomes in Patients With Solid Tumors
Lin, F. P. Y., Groza, T., Kocbek, S., Antezana, E., & Epstein, R. J. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00026 · Cited by 14
Assessing Treatment Benefit in Immuno-oncology
Buyse, M., Saad, E., Burzykowski, T., & Péron, J. (2020) · Statistics in Biosciences · doi:10.1007/s12561-020-09268-1
Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer
Zhou, H., Sun, Y., Xiu, W., Han, J., Zhong, L., Suo, J., Hao, W., Wang, Y., & Zhu, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03282-y · Cited by 13
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Watanabe, Y., Ogawa, M., Tamura, Y., Suda, S., Kaneko, M., Kumagawa, M., Hirayama, M., Matsumoto, N., Yamamoto, T., & Moriyama, M. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211058489 · Cited by 13
A case of hepatocellular carcinoma with “pseudoprogression” followed by complete response to atezolizumab plus bevacizumab
Odagiri, N., Tamori, A., Kotani, K., Motoyama, H., Kawamura, E., Hagihara, A., Fujii, H., Uchida‐Kobayashi, S., Enomoto, M., & Kawada, N. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01761-6 · Cited by 13
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
Nardo, M., Yilmaz, B., Nelson, B. E., Torres, H. A., Wang, L. S., Granwehr, B. P., Song, J., Pria, H. R. F. D., Trinh, V. A., Oliva, I. C. G., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad039 · Cited by 14
Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy
Hammer, M. M., Bagley, S. J., Aggarwal, C., Bauml, J. M., Nachiappan, A. C., Simone, C. B., Langer, C. J., & Katz, S. I. (2018) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2018.01.005 · Cited by 13
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges
Rutella, S., Cannarile, M. A., Gnjatic, S., Gomes, B., Guinney, J., Karanikas, V., Karkada, M., Kirkwood, J. M., Kotlán, B., Masucci, G. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001389 · Cited by 13
Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
Guo, H., Li, W., Qian, L., & Cui, J. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.02.08 · Cited by 13
PD‐L1 in circulating exosomes of Merkel cell carcinoma
Zanella, A., Vautrot, V., Aubin, F., Avoscan, L., Samimi, M., Garrido, C., Gobbo, J., & Nardin, C. (2022) · Experimental Dermatology · doi:10.1111/exd.14520 · Cited by 13
Personalized chemotherapy of lung cancer: What the radiologist should know
Ferretti, G., Reymond, E., Delouche, A., Sakhri, L., Jankowski, A., Moro‐Sibilot, D., Lantuéjoul, S., & Toffart, A. (2016) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2015.11.013 · Cited by 14
Using lymph node swelling as a potential biomarker for successful vaccination
Brewer, K., DeBay, D. R., Dude, I., Davis, C., Lake, K., Parsons, C., Rajagopalan, R., Weir, G. M., Stanford, M. M., Mansour, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9580 · Cited by 13
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology
Gridelli, C., Ascierto, P. A., Barberis, M. C. P., Felip, E., Garon, E. B., O'Brien, M. E. R., Senan, S., Casaluce, F., Sgambato, A., Papadimitrakopoulou, V., et al. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1234602 · Cited by 12
Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2
Castello, A., & Lopci, E. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03193-5 · Cited by 12
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Ferri, V., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01526-4 · Cited by 12
A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
Cao, S., Zhang, Y., Zhou, Y., Rong, W., Wang, Y., Ling, X., Zhang, L., Li, J., Tomita, Y., Watanabe, S., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-171 · Cited by 12
The Role of PET Molecular Imaging in Immune Checkpoint Inhibitor Therapy in Lung Cancer: Precision Medicine and Visual Monitoring
Yao, Y., Zhou, X., Zhang, A., Ma, X., Zhu, H., Yang, Z., & Li, N. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110200 · Cited by 10
Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis
Petrelli, F., Ghidini, A., Parati, M. C., Borgonovo, K., Rossitto, M., Ghilardi, M., Dognini, G. P., Petrò, D., Angeli, I., Lonati, V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186680 · Cited by 12
Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review
Li, J., Luo, Z., Jiang, S., & Li, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112200 · Cited by 12
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
Orillard, É., Adhikari, A., Malouf, R. S., Calais, F., Marchal, C., & Westeel, V. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015495 · Cited by 13
CD34+ Orbital Fibroblasts Contribute to the Pathogenesis of Thyroid Eye Disease via miR-182-5p
Yu, B., Wang, Y., Jin, J., Liu, J., Huang, Y., Wang, Y., Zhu, C., Li, Y., Li, B., Sun, J. P., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae876 · Cited by 12
The Role of [18F]FDG PET/CT in Monitoring of Therapy Response in Lung Cancer.
Ayeni, A. O., Evbuomwan, O., & Vangu, M. (2025) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2025.02.002 · Cited by 12
Imaging response assessment for oncology: An algorithmic approach
Ruchalski, K. L., Dewan, R., Sai, V., McIntosh, L., & Braschi‐Amirfarzan, M. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100426 · Cited by 12
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy
Rijavec, E., Genova, C., Barletta, G., Burrafato, G., Biello, F., Bello, M. G. D., Coco, S., Truini, A., Alama, A., Boccardo, F., et al. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.907786 · Cited by 11
Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology
Howard, S. A. H., Rosenthal, M. H., Jagannathan, J. P., Krajewski, K. M., Shinagare, A. B., Ramaiya, N. H., & Tirumani, S. H. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.12876 · Cited by 12
Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer
Maugeri‐Saccà, M., Barba, M., Vici, P., Pizzuti, L., Sergi, D., Catenaro, T., Lauro, L. D., Mottolese, M., Santini, D., Milella, M. S., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.004 · Cited by 11
Immunotherapy Beyond Progression in Advanced Renal Cell Carcinoma: A Case Report and Review of the Literature
Rebuzzi, S. E., Bregni, G., Grassi, M., Damiani, A., Buscaglia, M., Buti, S., & Fornarini, G. (2018) · Immunotherapy · doi:10.2217/imt-2018-0042 · Cited by 11
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy, E., Mezquita, L., Remón, J., & Besse, B. (2019) · Immunotherapy · doi:10.2217/imt-2019-0071 · Cited by 11
Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer
Philips, R. H. W., Han, C. J., Swendseid, B. P., Curry, J., Argiris, A. E., Luginbuhl, A., & Johnson, J. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682075 · Cited by 11
Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas
Ko, C., Chang, C.-H., Chen, T.-Y., Lim, S.-W., Wu, T., Chen, J., & Kuo, Y. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01662-7 · Cited by 11
Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1
Shi, H., Zeng, T., Liu, Y., Liang, Q., Yang, F., Liang, Y., Fu, Z., Li, W., Li, G., & Yin, Y. (2022) · ACS Materials Letters · doi:10.1021/acsmaterialslett.2c01036 · Cited by 10
Dual‐Sensing Nanoreporter for Dynamic and High‐Throughput Monitoring of Immune Checkpoint Inhibitor Responses in Tumor‐Derived Organoids
Nguyen, A., Ramesh, A., Fish, A., & Kulkarni, A. A. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202400393 · Cited by 10
A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence
Liu, X., Chen, H., Tan, G., Zhong, L., Jiang, H., Smith, S. M., & Wang, H. Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496627 · Cited by 10
Immunotherapy with Checkpoint Inhibitors for Lung Cancer: Novel Agents, Biomarkers and Paradigms
Monteiro, I., Califano, R., Mountzios, G., & de Mello, R. A. (2016) · Future Oncology · doi:10.2217/fon.15.309 · Cited by 10
Advanced Cancer Imaging Applied in the Comparative Setting
Vail, D. M., LeBlanc, A. K., & Jeraj, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00084 · Cited by 11
Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT
Tutino, F., Giovannini, E., Chiola, S., Giovacchini, G., & Ciarmiello, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103498 · Cited by 9
Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors
Jiang, C., Cai, X., Zhang, H., Xia, X., Zhang, B., & Xia, L. (2017) · Journal of Cancer · doi:10.7150/jca.21414 · Cited by 10
Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Lim, A. M. L., Cavanagh, K., Hicks, R. J., McLean, L. S., Goh, M., Webb, A., & Rischin, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656611 · Cited by 10
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study
Kataoka, Y., Hirano, K., Narabayashi, T., Hara, S., Fujimoto, D., Tanaka, T., Ebi, N., Tomii, K., & Yoshioka, H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3498-z · Cited by 10
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
Frega, S., Maso, A. D., Pasello, G., Cuppari, L., Bonanno, L., Conte, P., & Evangelista, L. (2020) · Cancers · doi:10.3390/cancers12051303 · Cited by 10
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9
Imaging spectrum of adverse events of immune checkpoint inhibitors
Shroff, G. S., Shroff, S., Ahuja, J., Truong, M. T., & Vlahos, I. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.11.117 · Cited by 9
Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy
Wang, D., Liu, S.-R., Fu, J., Zhang, P., Zheng, S., Qiu, B., Liu, H., Ye, Y., Guo, J., Zhou, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008574 · Cited by 9
Practical Approaches to Immunotherapy in the Clinic
Agarwala, S. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.10.001 · Cited by 9
The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors
Levi, J., & Hong, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1113924 · Cited by 9
RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment
Gong, A., Ruchalski, K. L., Kim, G. H. J., Douek, M. L., Gutiérrez, A., Patel, M. K., Sai, V., Coy, H., Villegas, B. E., Raman, S. S., et al. (2023) · Radiology Imaging Cancer · doi:10.1148/rycan.220166 · Cited by 9
Advanced urothelial cancer: a radiology update
Alessandrino, F., Ghaith, O. A., Williams, K. E., Sonpavde, G., Silverman, S. G., & Shinagare, A. B. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02148-3 · Cited by 9
The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art
Castello, A., & Lopci, E. (2019) · Current Radiopharmaceuticals · doi:10.2174/1874471012666191015100106 · Cited by 9
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
León-Mateos, L., García-Velloso, M., García-Figueiras, R., Rodríguez-Moreno, J., Vercher-Conejero, J., Sanchez, M., Gracia, J. L. P., Simó-Perdigó, M., & Gorospe, L. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-020-02442-3 · Cited by 7
Are radiologists ready to evaluate true response to immunotherapy?
Yirgin, İ. K., Ertürk, Ş. M., Doğan, İ., & Vatansever, S. (2021) · Insights into Imaging · doi:10.1186/s13244-021-00968-w · Cited by 9
Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be
Howard, S. A. H., Krajewski, K. M., Weissman, B. N., Seltzer, S. E., Ramaiya, N. H., & den Abbeele, A. D. V. (2015) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2015.03.044 · Cited by 9
Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST
ten Persigehl, T., Poeppel, T. D., & Sedlaczek, O. (2017) · Der Radiologe · doi:10.1007/s00117-017-0289-9 · Cited by 9

Authors: Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S.
Affiliations: Brigham and Women's Hospital (US)
Authors' Affiliations: Departments of 1Radiology and 2Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital; and 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
Corresponding author: Nishino, Mizuki
ORCID: Nishino, Mizuki
Ramaiya, Nikhil H.
Hodi, F. Stephen
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2013-07-15
Volume: 19
Issue: 14
Pages: 3936-3943
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-13-0895
PMC: PMC3740724
OpenAlex: W2153778867
Cited by: 522
References: 21
Citations by year: 2026: 19 · 2025: 21 · 2024: 27 · 2023: 53 · 2022: 51 · 2021: 56 · 2020: 76 · 2019: 57 · 2018: 49 · 2017: 39 · 2016: 36 · 2015: 23 · 2014: 13 · 2013: 2
FWCI: 13.12
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k23ca157631-02)
National Cancer Institute (K23-CA157631, 1K23CA157631)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: immune-related response criteria, tumor response assessment, immunotherapy, advanced melanoma, ipilimumab, interobserver variability, time to progression, best overall response, RECIST
MeSH terms: Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Terminology as Topic, Models, Statistical, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Statistics, Nonparametric, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks